GILLIS JONATHAN 4
4 · MapLight Therapeutics, Inc. · Filed Apr 17, 2026
Research Summary
AI-generated summary of this filing
MapLight (MPLT) CAAO Jonathan Gillis Sells 3,590 Shares
What Happened
Jonathan Gillis, CAAO and PAO of MapLight Therapeutics (MPLT), sold 3,590 shares in an open-market transaction on April 15, 2026. The weighted-average price was $26.61 per share (range $26.6045–$26.6093), for total proceeds of approximately $95,530. Footnote F1 states the sale represents the shares required to cover statutory tax withholding related to the vesting of restricted stock units (RSUs), so this sale appears routine rather than a discretionary investment decision.
Key Details
- Transaction date: 2026-04-15; Form 4 filed: 2026-04-17 (appears timely).
- Transaction type/code: Sale (S); amount: 3,590 shares.
- Price: Weighted average $26.61; reported per-share range $26.6045–$26.6093 (F2).
- Proceeds: ~ $95,530.
- Purpose: Tax-withholding sale to cover RSU vesting obligations (F1).
- Additional note: F3 indicates 121 shares were acquired under the issuer’s employee stock purchase plan on March 31, 2026.
- Shares owned after the transaction: Not specified in the provided excerpt.
Context
Tax-withholding sales tied to RSU vesting are common and usually considered routine administrative transactions rather than signals about an insider’s view of the company. The filing includes a weighted-average price disclosure and offers to provide per-trade details on request (F2).
Insider Transaction Report
- Sale
Voting Common Stock
[F1][F2][F3]2026-04-15$26.61/sh−3,590$95,530→ 251,054 total
Footnotes (3)
- [F1]Represents the number of shares required to be sold to cover the statutory tax withholding obligations in connection with the vesting of the restricted stock units.
- [F2]The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.6045 to $26.6093 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F3]Includes 121 shares acquired under the Issuer's stock purchase plan on March 31, 2026.